Bioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 Patients BOSTON, MASSACHUSETTS, Aug. 08, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral...

MATEON AND ASILI RESEARCH ALLIANCE ENTER INTO PARTNERSHIP FOR THE DEVELOPMENT OF ARTEMISININ AGAINST COVID-19 AGOURA HILLS, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, announced today the launch of its global observational study...

MATEON IS SELECTED BY IBM WATSON HEALTH FOR THE USE OF IBM CLINICAL DEVELOPMENT SOLUTION AT NO COST FOR PHASE II CLINICAL TRIAL OF OT-101 FOR COVID-19 Mateon was approved to use the platform following a review of the program as part of IBM Watson Health’s effort to help support and accelerate promising clinical COVID-19 candidates AGOURA HILLS,...

Increased Clotting in Severe COVID-19 Patients Complicates ECMO Treatment ITHACA, N.Y., May 01, 2020 (GLOBE NEWSWIRE) -- The authors of a new publication in the Journal of Thrombosis and Hematology identify Covid-19 coagulopathy as a hallmark sign of the disease’s...

Hydromer and N8 Medical Partner to Bring Life-Saving Coated ET Tubes for COVID-19 Patients CONCORD, NC, April 24, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Hydromer (OTCQB: HYDI) announced today that it will be the exclusive coating supplier and manufacturing partner for N8 Medical’s...